These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26293237)

  • 21. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Koo R; Lo J; Bock MJ
    Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
    Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
    Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
    Kuwano K; Hashino A; Asaki T; Hamamoto T; Yamada T; Okubo K; Kuwabara K
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1181-8. PubMed ID: 17545310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
    Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
    J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selexipag for the treatment of pulmonary arterial hypertension.
    Noel ZR; Kido K; Macaulay TE
    Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.
    Nakamura A; Yamada T; Asaki T
    Bioorg Med Chem; 2007 Dec; 15(24):7720-5. PubMed ID: 17881233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
    Demerouti EA; Karyofyllis P; Apostolopoulou SC
    Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selexipag for the treatment of pulmonary arterial hypertension.
    Skoro-Sajer N; Lang IM
    Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
    Kuwano K; Kosugi K; Fuchikami C; Funaki S
    Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selexipag: First Global Approval.
    Scott LJ
    Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
    Hoch M; Darpo B; Remenova T; Stoltz R; Zhou M; Kaufmann P; Bruderer S; Dingemanse J
    Drug Des Devel Ther; 2015; 9():175-85. PubMed ID: 25552906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular recognition and activation of the prostacyclin receptor by anti-pulmonary arterial hypertension drugs.
    Wang JJ; Jin S; Zhang H; Xu Y; Hu W; Jiang Y; Chen C; Wang DW; Xu HE; Wu C
    Sci Adv; 2024 Feb; 10(6):eadk5184. PubMed ID: 38335293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selexipag (Uptravi) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2016 Feb; 58(1488):21-3. PubMed ID: 26859660
    [No Abstract]   [Full Text] [Related]  

  • 36. Selexipag for the treatment of pulmonary arterial hypertension.
    Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
    Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles.
    Luo SB; Gu EM; Chen YA; Zhou SC; Fan C; Xu RA
    Pharm Biol; 2022 Dec; 60(1):1-8. PubMed ID: 34860644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension.
    Koestenberger M; Hansmann G
    Pediatr Cardiol; 2017 Oct; 38(7):1523-1524. PubMed ID: 28785777
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    Coghlan JG; Channick R; Chin K; Di Scala L; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Gaine S
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):37-47. PubMed ID: 29307087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
    Krause A; Machacek M; Lott D; Hurst N; Bruderer S; Dingemanse J
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):477-485. PubMed ID: 28556581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.